A collaboration between groups at MIT and Dana-Farber Cancer Institute led to the creation of a system that allows for quick determination of the susceptibility of cancer cells to specific drugs, without the need to rely on genomic markers. The technique consists of flowing the cells through vibrating microchannels, which lets the researchers obtain single… Read More »
Kyowa Kirin wants physicians to make the link between rare cancers that present on the skin to the blood connection underneath. Its new “Treat the Blood, Treat the Skin” campaign for Poteligeo, which is approved to treat two types of cutaneous lymphomas—mycosis fungoides and Sézary syndrome—is built on the insight that physicians often think of them as diseases… Read More »
Here’s some great news – a drug has been developed that cuts the likelihood of hereditary breast cancer caused by BRCA1 and BRCA2 genes coming back after treatment. The results show how the drug reduces the risk of recurrence, second cancers and death by 42%. The findings were so persuasive and clear that the trial… Read More »
Just two years ago, Roche’s Tecentriq was heralded as the first PD-1/L1 treatment to win an approval in triple-negative breast cancer. However, the approval was conditional on a postmarketing study on the Tencentriq and Celgene’s Abraxane combo which later failed. Now Roche is pulling the plug. The Swiss pharma on Friday announced that it has voluntarily withdrawn its accelerated approval for Tecentriq in… Read More »